Ventyx Biosciences released Phase II data showing its oral NLRP3 inhibitor produced rapid and sustained reductions in hsCRP and other inflammation‑related biomarkers in patients with obesity and cardiovascular risk factors. The compound did not meet weight‑loss endpoints but produced cardiometabolic signal that the company and analysts say could support development in cardiovascular and liver disease indications. Ventyx said positive biomarker and safety data have triggered business development interest and preliminary partnership discussions with larger pharmas. NLRP3 remains an attractive anti‑inflammatory axis; an oral, once‑daily agent would be commercially differentiated if clinical outcomes are confirmed.